Working with Ex Vivo Organ Perfusion to support the management of inflammatory processes
*Not authorized / cleared / approved in the US
The ECOS-300CY® is a CE-marked device indicated for the adsorptive removal of cytokines and other inflammatory mediators during ex vivo organ perfusion (EVOP).
EVOP is a recently established technique in solid-organ transplantation in which harvested organs — such as the heart, lungs, liver, or kidneys — are perfused with oxygenated, temperature-controlled blood or perfusate outside the body.
Inflammatory mediator adsorption and organ preservation — demonstrated in clinical and preclinical studies.
Removal of IL-6
Reduction of TNF alpha
Versatile application in a variety of organs and EVOP platforms
The ECOS-300CY® Therapy System is a CE marked device specifically approved in the EU for the removal of cytokines and other inflammatory mediators during ex vivo organ perfusion.
ECOS-300CY is a high-flow, low-resistance adsorber designed for easy integration into the perfusate flow of an Ex Vivo Organ Perfusion (EVOP) circuit.
The therapy is intended for the adsorptive reduction of certain inflammatory mediators during ex vivo organ perfusion, aiming to support organ conditioning and preservation prior to transplantation.
Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.
The combination of Ex Vivo Organ Perfusion (EVOP) with the ECOS300CY® sorbent cartridge represents an emerging approach for supporting organ conditioning and preservation prior to transplantation.
Published preclinical and clinical experiences with ex vivo perfusion of solid organs demonstrate the feasibility of integrating hemoadsorption into perfusion circuits and suggest potential benefits for organ preservation and reconditioning.
The ECOS-300CY cartridge is available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.
-
ECOS-300CY is a high-flow, low-resistance adsorber designed for easy integration into the perfusate flow of an Ex Vivo Organ Perfusion (EVOP) circuit.
The therapy is intended for the adsorptive reduction of certain inflammatory mediators during ex vivo organ perfusion, aiming to support organ conditioning and preservation prior to transplantation. -
Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.
-
The combination of Ex Vivo Organ Perfusion (EVOP) with the ECOS300CY® sorbent cartridge represents an emerging approach for supporting organ conditioning and preservation prior to transplantation.
Published preclinical and clinical experiences with ex vivo perfusion of solid organs demonstrate the feasibility of integrating hemoadsorption into perfusion circuits and suggest potential benefits for organ preservation and reconditioning. -
The ECOS-300CY cartridge is available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.
Additional Information
- Hosgood SA et al., J Transl Med. 2017; 15(1):216
- Iskender I et al., JTCVS. 2021; 161(2):e109-e121
- Lindstedt S et al., J Heart Lung Transplant. 2023; 42(10):1358-1362
- Boffini M et al., Transplant Int. 2023; 36:10777
- Niromand A et al., Front Cardiovasc Med. 2023; 10:127444
ECOS-300CY IFU Indications (11/2022): ECOS is indicated for use during the ex vivo perfusion of harvested organs to remove inflammatory mediators from the perfusion solution by adsorption. ECOS has been shown to reduce levels of inflammatory mediators from Belzer and Steen perfusion solutions. Maximum Treatment Time per Device: 24 hours.
Contact us to learn more about ECOS – 300CY Therapy
Get in touch